Table 1

Patient demographic and clinical characteristics at baseline in TP2 (ITT population)

ADL-PF/ADL-PF
(n=283)
ADL-EU/ADL-EU
(n=135)
ADL-EU/ADL-PF
(n=134)
Demographics
 Gender, n (%)
 Female229 (80.9)108 (80.0)95 (70.9)
 Male54 (19.1)27 (20.0)39 (29.1)
 Age, mean (SD), years51.3 (13.7)53.6 (12.1)53.4 (13.4)
 Weight, mean (SD), kg74.6 (17.7)76.2 (20.4)75.7 (18.7)
 BMI, mean (SD), kg/m2 27.5 (6.2)28.4 (7.4)27.5 (6.4)
 Race, n (%)
 White250 (88.3)113 (83.7)116 (86.6)
 Black6 (2.1)7 (5.2)2 (1.5)
 Asian14 (4.9)8 (5.9)6 (4.5)
 Other13 (4.6)7 (5.2)10 (7.5)
Clinical characteristics
 RA duration, mean (SD), years6.9 (7.3)7.1 (6.6)6.6 (7.0)
 Swollen joint count (66), mean (SD)15.1 (7.7)17.1 (9.6)17.0 (10.3)
 Tender joint count (68), mean (SD)23.7 (11.9)26.8 (14.7)25.5 (15.0)
 hs-CRP, mg/L, mean (SD)21.2 (22.5)22.0 (24.5)22.3 (25.9)
 DAS28–4(CRP), mean (SD)5.9 (0.9)6.1 (0.8)6.0 (1.0)
 HAQ-DI, mean (SD)1.5 (0.6)1.6 (0.7)1.7 (0.6)
 Prior use of one biologic*, n (%)8 (2.8)4 (3.0)1 (0.7)
 Number of prior and current non-biologic DMARDs (in addition to MTX), mean (SD)1.5 (0.9)1.5 (0.9)1.5 (0.8)
 MTX dose, mean (SD), mg/week15.2 (4.4)15.7 (4.7)14.7 (4.0)
 Corticosteroid use, n (%)155 (54.8)77 (57.0)80 (59.7)
  • *Includes the use of no more than two doses of one non-adalimumab biologic drug.

  • ADL-EU, reference adalimumab sourced from the European Union; ADL-PF, PF-06410293; BMI, body mass index; CRP, C-reactive protein; DAS28-4(CRP), Disease Activity Score-28: 4 components using CRP; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire–Disability Index; hs-CRP, high-sensitivity CRP; ITT, intent-to-treat; MTX, methotrexate; RA, rheumatoid arthritis; TP2, treatment period 2.